Protein Kinase C-β as a Therapeutic Target in Breast Cancer

George W. Sledge, Yesim Polar

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Combining existing breast cancer therapies with novel agents that interfere with major signaling pathways is a promising approach. Targeting protein kinase C (PKC)-β may serve as an attractive candidate in this regard for the following reasons: first, PKC-β II (a splice variant of PKC-β) has been implicated in tumorigenesis in human and rodent models. Second, PKC-β, mainly PKC-βII, is the predominant mediator of vascular endothelial growth factor-induced endothelial cell proliferation, which is a well-known stimulator of tumor angiogenesis and growth in breast cancer. There is increasing evidence that PKC-β-selective inhibitors are effective in both preclinical and clinical trials. Enzastaurin, a potent inhibitor of PKC-β, suppresses both tumor growth and tumor-induced angiogenesis in human tumor xenografts. Phase II trials of enzastaurin in recurrent high-grade gliomas and lymphomas have shown promising results. A similar compound, ruboxistaurin, is also under investigation in clinical trials for diabetic complications. This review focuses on the rationale for using PKC-β as a therapeutic target at both the preclinical and clinical levels in breast cancer.

Original languageEnglish
Pages (from-to)15-18
Number of pages4
JournalSeminars in Oncology
Volume33
Issue numberSUPPL. 9
DOIs
StatePublished - Jun 2006

Fingerprint

Protein Kinase C
Breast Neoplasms
Therapeutics
ruboxistaurin
Neoplasms
Clinical Trials
Angiogenesis Inducing Agents
Diabetes Complications
Growth
Heterografts
Glioma
Non-Hodgkin's Lymphoma
Vascular Endothelial Growth Factor A
Rodentia
Carcinogenesis
Endothelial Cells
Cell Proliferation

ASJC Scopus subject areas

  • Oncology

Cite this

Protein Kinase C-β as a Therapeutic Target in Breast Cancer. / Sledge, George W.; Polar, Yesim.

In: Seminars in Oncology, Vol. 33, No. SUPPL. 9, 06.2006, p. 15-18.

Research output: Contribution to journalArticle

Sledge, George W. ; Polar, Yesim. / Protein Kinase C-β as a Therapeutic Target in Breast Cancer. In: Seminars in Oncology. 2006 ; Vol. 33, No. SUPPL. 9. pp. 15-18.
@article{9a167229d1a44c43b10343cfde8286f2,
title = "Protein Kinase C-β as a Therapeutic Target in Breast Cancer",
abstract = "Combining existing breast cancer therapies with novel agents that interfere with major signaling pathways is a promising approach. Targeting protein kinase C (PKC)-β may serve as an attractive candidate in this regard for the following reasons: first, PKC-β II (a splice variant of PKC-β) has been implicated in tumorigenesis in human and rodent models. Second, PKC-β, mainly PKC-βII, is the predominant mediator of vascular endothelial growth factor-induced endothelial cell proliferation, which is a well-known stimulator of tumor angiogenesis and growth in breast cancer. There is increasing evidence that PKC-β-selective inhibitors are effective in both preclinical and clinical trials. Enzastaurin, a potent inhibitor of PKC-β, suppresses both tumor growth and tumor-induced angiogenesis in human tumor xenografts. Phase II trials of enzastaurin in recurrent high-grade gliomas and lymphomas have shown promising results. A similar compound, ruboxistaurin, is also under investigation in clinical trials for diabetic complications. This review focuses on the rationale for using PKC-β as a therapeutic target at both the preclinical and clinical levels in breast cancer.",
author = "Sledge, {George W.} and Yesim Polar",
year = "2006",
month = "6",
doi = "10.1053/j.seminoncol.2006.03.019",
language = "English",
volume = "33",
pages = "15--18",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. 9",

}

TY - JOUR

T1 - Protein Kinase C-β as a Therapeutic Target in Breast Cancer

AU - Sledge, George W.

AU - Polar, Yesim

PY - 2006/6

Y1 - 2006/6

N2 - Combining existing breast cancer therapies with novel agents that interfere with major signaling pathways is a promising approach. Targeting protein kinase C (PKC)-β may serve as an attractive candidate in this regard for the following reasons: first, PKC-β II (a splice variant of PKC-β) has been implicated in tumorigenesis in human and rodent models. Second, PKC-β, mainly PKC-βII, is the predominant mediator of vascular endothelial growth factor-induced endothelial cell proliferation, which is a well-known stimulator of tumor angiogenesis and growth in breast cancer. There is increasing evidence that PKC-β-selective inhibitors are effective in both preclinical and clinical trials. Enzastaurin, a potent inhibitor of PKC-β, suppresses both tumor growth and tumor-induced angiogenesis in human tumor xenografts. Phase II trials of enzastaurin in recurrent high-grade gliomas and lymphomas have shown promising results. A similar compound, ruboxistaurin, is also under investigation in clinical trials for diabetic complications. This review focuses on the rationale for using PKC-β as a therapeutic target at both the preclinical and clinical levels in breast cancer.

AB - Combining existing breast cancer therapies with novel agents that interfere with major signaling pathways is a promising approach. Targeting protein kinase C (PKC)-β may serve as an attractive candidate in this regard for the following reasons: first, PKC-β II (a splice variant of PKC-β) has been implicated in tumorigenesis in human and rodent models. Second, PKC-β, mainly PKC-βII, is the predominant mediator of vascular endothelial growth factor-induced endothelial cell proliferation, which is a well-known stimulator of tumor angiogenesis and growth in breast cancer. There is increasing evidence that PKC-β-selective inhibitors are effective in both preclinical and clinical trials. Enzastaurin, a potent inhibitor of PKC-β, suppresses both tumor growth and tumor-induced angiogenesis in human tumor xenografts. Phase II trials of enzastaurin in recurrent high-grade gliomas and lymphomas have shown promising results. A similar compound, ruboxistaurin, is also under investigation in clinical trials for diabetic complications. This review focuses on the rationale for using PKC-β as a therapeutic target at both the preclinical and clinical levels in breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=33745200542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745200542&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2006.03.019

DO - 10.1053/j.seminoncol.2006.03.019

M3 - Article

C2 - 16797377

AN - SCOPUS:33745200542

VL - 33

SP - 15

EP - 18

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - SUPPL. 9

ER -